ArticleCancers2019

Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma.

Yuji Eso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.